1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021; Revenue Guidance for the Full Year 2022

01/09/2022 | 04:00pm EDT

Exelixis, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year 2021 and revenue guidance for the full year 2022. For the quarter, the company expects revenue to be $300 million. For the full year 2021, the company expects revenue to be $1.08 billion. For the full year 2022 the company expects revenue to be in the range of $1.325 billion to $1.425 billion.


© S&P Capital IQ 2022
All news about EXELIXIS, INC.
05/27EXELIXIS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vot..
AQ
05/26Exelixis Details Results of Two Cancer Trials of Cabozantinib in Combination With Pembr..
MT
05/26Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung C..
BU
05/26Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembr..
BU
05/26Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with..
CI
05/17TRANSCRIPT : Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference, ..
CI
05/11TRANSCRIPT : Exelixis, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/10TRANSCRIPT : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
05/10EXELIXIS : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2022 1 587 M - -
Net income 2022 291 M - -
Net cash 2022 1 276 M - -
P/E ratio 2022 20,6x
Yield 2022 -
Capitalization 5 902 M 5 902 M -
EV / Sales 2022 2,92x
EV / Sales 2023 2,40x
Nbr of Employees 954
Free-Float 97,7%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 18,40 $
Average target price 26,45 $
Spread / Average Target 43,8%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.0.66%5 902
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958